CureVac NV
http://www.curevac.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CureVac NV
CureVac Takes Another Shot At mRNA Vaccines, Expands Cancer Work
Its first COVID-19 vaccine failed last year, but fueled by payments from the EU, Germany and GSK, CureVac is trying again with two further versions of its mRNA platform.
Gaming Industry Entrepreneur Backs Ethris To Be Germany’s Next mRNA Pioneer
An online gaming entrepreneur is injecting new cash and strategic thinking into biotech Ethris – with the goal of making it a ‘gamechanger’ in inhaleable mRNA.
Cellino Raises $80m Series A To Transform Stem Cell Therapy Manufacturing
The Cambridge, MA start-up aims to ‘democratize’ therapies based on induced pluripotent stem cells by developing an automated manufacturing system.
China mRNA Player Abogen Gets $300m More As Country Eyes Omicron Threat
From inactivated virus-based to mRNA platforms, the race is on in China to develop vaccines to fight the latest omicron variant, with substantial new funding pouring into one young mRNA company.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- CureVac GmbH
- CureVac BV